Study on the Effectiveness of Moxifloxacin and Clarithromycin in Treating Community Acquired Pneumonia
Abstract
Objective: To evaluate the moxifloxacin effectiveness in treating community acquired pneumonia. Method: By using of randomized controlled clinical trial.60 patients were randomly assigned to the case group with moxifloxacin and the control group with clarithromycin, both groups were 30 cases, doses of both groups were taken orally 400mg/d qd and 500mg/d bid respectively, the therapy duration was 7～14 days. Result: The total clinical effective rate of both groups were 96.6% and 92.8%respectively,and bacteria eliminating rate were 100% and 92.8% respectively, and the rate of advrerse reaction were 6.9% and 10.3% respectively. Conclusion: There is no significanf difference in the clinical effectiveness and the rate of adverse reaction between two groups, so moxifloxacin is aslo an effective and safe antibacterial drug in treating community acquired pneumonia.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 60 participants or records.
Read the paper
Related studies
- Structural and topological analysis of thiosemicarbazone-based metal complexes: computational and experimental study of bacterial biofilm inhibition and antioxidant activity
- Toward better cures for Mycobacterium abscessus lung disease
- Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing
- Design, Synthesis and In vitro Antitubercular Effect of New Chalcone Derivatives Coupled with 1,2,3‐Triazoles: A Computational Docking Techniques
- Upregulation of pmrA, pmrB, pmrC, phoQ, phoP, and arnT genes contributing to resistance to colistin in superbug Klebsiella pneumoniae isolates from human clinical samples in Tehran, Iran
- Whole-genome sequencing of clinical isolates of Citrobacter Europaeus in China carrying blaOXA−48 and blaNDM−1
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.